<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:00:47Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10852367" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10852367</identifier>
        <datestamp>2024-02-09</datestamp>
        <setSpec>jco</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Clin Oncol</journal-id>
              <journal-id journal-id-type="hwp">jco</journal-id>
              <journal-id journal-id-type="publisher-id">JCO</journal-id>
              <journal-title-group>
                <journal-title>Journal of Clinical Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0732-183X</issn>
              <issn pub-type="epub">1527-7755</issn>
              <publisher>
                <publisher-name>Wolters Kluwer Health</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10852367</article-id>
              <article-id pub-id-type="pmcid">PMC10852367</article-id>
              <article-id pub-id-type="pmc-uid">10852367</article-id>
              <article-id pub-id-type="pmid">37369081</article-id>
              <article-id pub-id-type="pmid">37369081</article-id>
              <article-id pub-id-type="publisher-id">JCO.22.02887</article-id>
              <article-id pub-id-type="doi">10.1200/JCO.22.02887</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>ORIGINAL REPORTS</subject>
                  <subj-group>
                    <subject>Genitourinary Cancer</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2650-0049</contrib-id>
                  <name>
                    <surname>O'Donnell</surname>
                    <given-names>Peter H.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="con1" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8965-8129</contrib-id>
                  <name>
                    <surname>Milowsky</surname>
                    <given-names>Matthew I.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="con2" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6165-5797</contrib-id>
                  <name>
                    <surname>Petrylak</surname>
                    <given-names>Daniel P.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="con3" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8980-2410</contrib-id>
                  <name>
                    <surname>Hoimes</surname>
                    <given-names>Christopher J.</given-names>
                  </name>
                  <degrees>DO</degrees>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="con4" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6145-9040</contrib-id>
                  <name>
                    <surname>Flaig</surname>
                    <given-names>Thomas W.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="con5" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2485-6201</contrib-id>
                  <name>
                    <surname>Mar</surname>
                    <given-names>Nataliya</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="con6" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Moon</surname>
                    <given-names>Helen H.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                  <xref rid="con7" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3630-4941</contrib-id>
                  <name>
                    <surname>Friedlander</surname>
                    <given-names>Terence W.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                  <xref rid="con8" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0581-7963</contrib-id>
                  <name>
                    <surname>McKay</surname>
                    <given-names>Rana R.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                  <xref rid="con9" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4003-1103</contrib-id>
                  <name>
                    <surname>Bilen</surname>
                    <given-names>Mehmet A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff10" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                  <xref rid="con10" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Srinivas</surname>
                    <given-names>Sandy</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff11" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                  <xref rid="con11" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4293-4680</contrib-id>
                  <name>
                    <surname>Burgess</surname>
                    <given-names>Earle F.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff12" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                  <xref rid="con12" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3935-9638</contrib-id>
                  <name>
                    <surname>Ramamurthy</surname>
                    <given-names>Chethan</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff13" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                  <xref rid="con13" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0444-5870</contrib-id>
                  <name>
                    <surname>George</surname>
                    <given-names>Saby</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff14" ref-type="aff">
                    <sup>14</sup>
                  </xref>
                  <xref rid="con14" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1423-5295</contrib-id>
                  <name>
                    <surname>Geynisman</surname>
                    <given-names>Daniel M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff15" ref-type="aff">
                    <sup>15</sup>
                  </xref>
                  <xref rid="con15" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0703-2959</contrib-id>
                  <name>
                    <surname>Bracarda</surname>
                    <given-names>Sergio</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff16" ref-type="aff">
                    <sup>16</sup>
                  </xref>
                  <xref rid="con16" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Borchiellini</surname>
                    <given-names>Delphine</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff17" ref-type="aff">
                    <sup>17</sup>
                  </xref>
                  <xref rid="con17" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Geoffrois</surname>
                    <given-names>Lionnel</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff18" ref-type="aff">
                    <sup>18</sup>
                  </xref>
                  <xref rid="con18" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Maroto Rey</surname>
                    <given-names>Jose Pablo</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff19" ref-type="aff">
                    <sup>19</sup>
                  </xref>
                  <xref rid="con19" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ferrario</surname>
                    <given-names>Christiano</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff20" ref-type="aff">
                    <sup>20</sup>
                  </xref>
                  <xref rid="con20" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6723-6948</contrib-id>
                  <name>
                    <surname>Carret</surname>
                    <given-names>Anne-Sophie</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff21" ref-type="aff">
                    <sup>21</sup>
                  </xref>
                  <xref rid="con21" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yu</surname>
                    <given-names>Yao</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff21" ref-type="aff">
                    <sup>21</sup>
                  </xref>
                  <xref rid="con22" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Guseva</surname>
                    <given-names>Maria</given-names>
                  </name>
                  <degrees>MD, PharmD</degrees>
                  <xref rid="aff22" ref-type="aff">
                    <sup>22</sup>
                  </xref>
                  <xref rid="con23" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Homet Moreno</surname>
                    <given-names>Blanca</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="aff23" ref-type="aff">
                    <sup>23</sup>
                  </xref>
                  <xref rid="con24" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2637-4249</contrib-id>
                  <name>
                    <surname>Rosenberg</surname>
                    <given-names>Jonathan E.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff24" ref-type="aff">
                    <sup>24</sup>
                  </xref>
                  <xref rid="cor1" ref-type="corresp"/>
                  <xref rid="con25" ref-type="fn"/>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>University of Chicago, Chicago, IL</aff>
                <aff id="aff2"><label><sup>2</sup></label>University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC</aff>
                <aff id="aff3"><label><sup>3</sup></label>Yale Cancer Center, New Haven, CT</aff>
                <aff id="aff4"><label><sup>4</sup></label>Duke Cancer Institute, Duke University, Durham, NC</aff>
                <aff id="aff5"><label><sup>5</sup></label>University of Colorado Comprehensive Cancer Center, Aurora, CO</aff>
                <aff id="aff6"><label><sup>6</sup></label>University of California at Irvine, Irvine, CA</aff>
                <aff id="aff7"><label><sup>7</sup></label>Kaiser Permanente Southern California, Riverside, CA</aff>
                <aff id="aff8"><label><sup>8</sup></label>University of California at San Francisco, San Francisco, CA</aff>
                <aff id="aff9"><label><sup>9</sup></label>University of California at San Diego, San Diego, CA</aff>
                <aff id="aff10"><label><sup>10</sup></label>Emory University Winship Cancer Institute, Atlanta, GA</aff>
                <aff id="aff11"><label><sup>11</sup></label>Stanford Cancer Center, Stanford, CA</aff>
                <aff id="aff12"><label><sup>12</sup></label>Levine Cancer Center, Charlotte, NC</aff>
                <aff id="aff13"><label><sup>13</sup></label>University of Texas Health Sciences Center at San Antonio, San Antonio, TX</aff>
                <aff id="aff14"><label><sup>14</sup></label>Roswell Park Cancer Center, Buffalo, NY</aff>
                <aff id="aff15"><label><sup>15</sup></label>Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA</aff>
                <aff id="aff16"><label><sup>16</sup></label>Azienda Ospedaliera Santa Maria di Terni, Terni, Italy</aff>
                <aff id="aff17"><label><sup>17</sup></label>Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France</aff>
                <aff id="aff18"><label><sup>18</sup></label>Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France</aff>
                <aff id="aff19"><label><sup>19</sup></label>Hospital de la Santa Creu i Sant Paul, Barcelona, Spain</aff>
                <aff id="aff20"><label><sup>20</sup></label>Jewish General Hospital, Montreal, Quebec, Canada</aff>
                <aff id="aff21"><label><sup>21</sup></label>Seagen Inc, Bothell, WA</aff>
                <aff id="aff22"><label><sup>22</sup></label>Astellas Pharma, Northbrook, IL</aff>
                <aff id="aff23"><label><sup>23</sup></label>Merck &amp; Co Inc, Rahway, NJ</aff>
                <aff id="aff24"><label><sup>24</sup></label>Memorial Sloan Kettering Cancer Center, New York, NY</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065; Twitter: @DrRosenbrgMSK; e-mail: <email>rosenbj1@mskcc.org</email>.</corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>1</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>27</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>27</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>41</volume>
              <issue>25</issue>
              <fpage>4107</fpage>
              <lpage>4117</lpage>
              <history>
                <date date-type="received">
                  <day>21</day>
                  <month>12</month>
                  <year>2022</year>
                </date>
                <date date-type="rev-recd">
                  <day>26</day>
                  <month>3</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>10</day>
                  <month>5</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2023 by American Society of Clinical Oncology</copyright-statement>
                <copyright-year>2023</copyright-year>
                <copyright-holder>American Society of Clinical Oncology</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri xlink:href="jco-41-4107.pdf"/>
              <related-article related-article-type="companion" ext-link-type="doi" id="r1" xlink:href="10.1200/JCO.23.00987"/>
              <related-object source-id-type="registry-name" document-id="NCT03288545" document-id-type="clinical-trial-number" source-type="clinical-trials-registry" source-id="ClinicalTrials.gov" id="d64e458"/>
              <abstract>
                <sec>
                  <title>PURPOSE</title>
                  <p>Patients with locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible for cisplatin-based therapy have limited first-line (1L) treatment options and significant need for improved therapies. Enfortumab vedotin (EV) and pembrolizumab (Pembro) individually have shown a survival benefit in urothelial cancer in second-line + la/mUC settings. Here, we present data from the pivotal trial of EV plus Pembro (EV + Pembro) in the 1L setting.</p>
                </sec>
                <sec>
                  <title>PATIENTS AND METHODS</title>
                  <p>In Cohort K of the EV-103 phase Ib/II study, cisplatin-ineligible patients with previously untreated la/mUC were randomly assigned 1:1 to receive EV as monotherapy or in combination with Pembro. The primary end point was confirmed objective response rate (cORR) per blinded independent central review. Secondary end points included duration of response (DOR) and safety. There were no formal statistical comparisons between treatment arms.</p>
                </sec>
                <sec>
                  <title>RESULTS</title>
                  <p>The cORR was 64.5% (95% CI, 52.7 to 75.1) and 45.2% (95% CI, 33.5 to 57.3) for patients treated with EV + Pembro (N = 76) and EV monotherapy (N = 73), respectively. The median DOR was not reached for the combination and was 13.2 months for monotherapy; 65.4% and 56.3% of patients who responded to the combination and monotherapy, respectively, maintained a response at 12 months. The most common grade 3 or higher treatment-related adverse events (TRAEs) in patients treated with the combination were maculopapular rash (17.1%), fatigue (9.2%), and neutropenia (9.2%). EV TRAEs of special interest (any grade) in the combination arm included skin reactions (67.1%) and peripheral neuropathy (60.5%).</p>
                </sec>
                <sec>
                  <title>CONCLUSION</title>
                  <p>EV + Pembro showed a high cORR with durable responses as 1L treatment in cisplatin-ineligible patients with la/mUC. Patients who received EV monotherapy had a response and safety profile consistent with previous studies. Adverse events for EV + Pembro were manageable, with no new safety signals observed.</p>
                </sec>
              </abstract>
              <counts>
                <fig-count count="8"/>
                <table-count count="5"/>
                <equation-count count="0"/>
                <ref-count count="37"/>
                <page-count count="18"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="introduction">
              <title>INTRODUCTION</title>
              <p>The occurrence of urothelial cancer is increasing worldwide, with locally advanced or metastatic urothelial cancer (la/mUC) demonstrating an especially poor prognosis.<sup><xref rid="b1" ref-type="bibr">1</xref>-<xref rid="b4" ref-type="bibr">4</xref></sup> Cisplatin-based chemotherapy is the gold standard first-line (1L) treatment in patients with la/mUC, but approximately half of all patients are ineligible for 1L cisplatin-based chemotherapy because of impaired renal function, poor performance status, and other comorbidities.<sup><xref rid="b5" ref-type="bibr">5</xref>-<xref rid="b8" ref-type="bibr">8</xref></sup> Carboplatin plus gemcitabine is a commonly used regimen for cisplatin-ineligible patients but has shown lower activity and poor tolerability.<sup><xref rid="b9" ref-type="bibr">9</xref>-<xref rid="b12" ref-type="bibr">12</xref></sup> Other therapeutic options exist but are limited to subgroups of patients; avelumab maintenance therapy is approved for patients who have remained free from disease progression after 1L platinum-based treatment and has shown improved survival; however, only patients who do not progress after four to six cycles of 1L therapy are eligible.<sup><xref rid="b13" ref-type="bibr">13</xref>,<xref rid="b14" ref-type="bibr">14</xref></sup> Single-agent PD-1/PD-L1 checkpoint inhibitors (CPIs) may be another 1L option for cisplatin-ineligible patients; however, they have become increasingly restricted to certain populations. In the United States currently, pembrolizumab (Pembro) is limited to 1L patients who are not eligible for any platinum-based chemotherapy.<sup><xref rid="b15" ref-type="bibr">15</xref>-<xref rid="b19" ref-type="bibr">19</xref></sup> Additionally, approximately 60% of cisplatin-ineligible patients with la/mUC who receive 1L treatment do not receive second-line (2L) treatment.<sup><xref rid="b20" ref-type="bibr">20</xref></sup> This underscores the need for efficacious and tolerable 1L therapies.</p>
              <boxed-text id="B1" position="anchor">
                <sec sec-type="context-box">
                  <title>CONTEXT</title>
                  <p>
                    <list list-type="simple">
                      <list-item>
                        <p>
                          <bold>Key Objective</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>To assess the efficacy, tolerability, and safety of enfortumab vedotin (EV) in combination with pembrolizumab (Pembro) in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer.</p>
                      </list-item>
                      <list-item>
                        <p>
                          <bold>Knowledge Generated</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>EV + Pembro showed a high confirmed objective response rate of 64.5%, and rapid and durable responses, with 65.4% of responders maintaining a response at 12 months (Kaplan-Meier estimate). The combination demonstrated a manageable safety profile.</p>
                      </list-item>
                      <list-item>
                        <p>
                          <bold>Relevance <italic toggle="yes">(M.A. Carducci)</italic></bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>This report provides a strong foundation for the ongoing phase III studies of the EV and Pembro combination in muscle invasive bladder cancer. Toxicities although manageable are increased over EV alone and maturation of the survival data may also shed light on addressing toxicity, both clinical and financial, concerns as well as sequencing approaches.*</p>
                        <p>*Relevance section written by <italic toggle="yes">JCO</italic> Associate Editor Michael A. Carducci, MD.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
              </boxed-text>
              <p>Enfortumab vedotin (EV), an antibody-drug conjugate (ADC), comprises a fully human monoclonal antibody specific for nectin-4 and monomethyl auristatin E (MMAE). EV delivers MMAE to cells expressing nectin-4, leading to cell cycle arrest and cell death. Pembro is an anti–PD-1 antibody that uses the PD-1 receptor as a therapeutic target and has antitumor activity in multiple tumor types.<sup><xref rid="b16" ref-type="bibr">16</xref></sup></p>
              <p>EV and Pembro as individual agents have shown overall survival (OS) benefits compared with 2L or third-line treatment in patients with la/mUC.<sup><xref rid="b16" ref-type="bibr">16</xref>,<xref rid="b21" ref-type="bibr">21</xref>,<xref rid="b22" ref-type="bibr">22</xref></sup> Preclinical data have shown that vedotin ADCs, including EV, in combination with PD-1/PD-L1 inhibitors such as Pembro, may enhance antitumor activity relative to their respective mechanisms of action and support complimentary efficacy.<sup><xref rid="b23" ref-type="bibr">23</xref>-<xref rid="b25" ref-type="bibr">25</xref></sup></p>
              <p>In the phase Ib/II study EV-103, results from the Dose Escalation/Cohort A demonstrated high antitumor activity and durable responses with encouraging survival and a manageable safety profile for EV plus Pembro (EV + Pembro), providing the rationale for further evaluation.<sup><xref rid="b26" ref-type="bibr">26</xref></sup> Randomized Cohort K is intended to provide efficacy and safety data on the treatment combination. The EV monotherapy arm was included to better understand the safety and efficacy of EV monotherapy in 1L cisplatin-ineligible patients. No statistical comparison between treatment arms was performed.</p>
              <p>Here, we present the efficacy and safety results of EV-103 randomized Cohort K for cisplatin-ineligible patients with la/mUC treated with EV + Pembro or EV monotherapy in the 1L setting.</p>
            </sec>
            <sec sec-type="patients|methods">
              <title>PATIENTS AND METHODS</title>
              <sec>
                <title>Trial Participants</title>
                <p>In Cohort K of the EV-103 study, eligible patients were 18 years or older with histologically documented la/mUC, including squamous differentiation or mixed cell types. Patients had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 2 or less and were eligible for Pembro therapy. Patients in Cohort K were deemed ineligible for cisplatin-based chemotherapy on the basis of at least one of the following: glomerular filtration rate (GFR) &lt;60 mL/min and ≥30 mL/min, grade ≥ 2 hearing loss, ECOG PS of 2, or New York Heart Association (NYHA) Class III heart failure. Patients with an ECOG PS of 2 met additional criteria: hemoglobin ≥ 10 g/dL, GFR ≥ 50 mL/min, and no NYHA Class III heart failure. Patients were excluded from the trial if they had any of the following: previous systemic treatment for locally advanced or metastatic disease, including adjuvant/neoadjuvant platinum-based therapy within 12 months before random assignment, previous treatment with a PD-1, PD-L1, or PD-L2 inhibitor, or any previous treatment with stimulatory or coinhibitory T-cell receptor agents, previous treatment with EV or another MMAE-based ADC, ongoing grade 2 or higher sensory or motor neuropathy, or ongoing clinically significant toxic effects associated with previous treatment, active central nervous system metastases, or uncontrolled diabetes (defined as hemoglobin A1c [HbA1c] ≥ 8% or HbA1c 7% to &lt;8% with associated diabetes symptoms [polyuria or polydipsia] that were not otherwise explained). Full eligibility criteria are provided in the study Protocol (online only).</p>
              </sec>
              <sec>
                <title>Random Assignment and Treatment</title>
                <p>Enrolled patients were randomly assigned 1:1 to receive EV alone or in combination with Pembro. Random assignment was stratified by ECOG PS (0 <italic toggle="yes">v</italic> 1 or 2) and liver metastasis (present <italic toggle="yes">v</italic> absent) at baseline. EV was administered at a dose of 1.25 mg per kilogram of body weight (maximum total dose of 125 mg) as a single intravenous infusion over 30 minutes on days 1 and 8 of a 3-week cycle. Pembro was administered at a dose of 200 mg as a single intravenous infusion over 30 minutes on day 1 of a 3-week cycle. Dose modifications and reductions were permitted to manage treatment-related adverse events (TRAEs) as described in the study Protocol.</p>
              </sec>
              <sec>
                <title>Trial Oversight</title>
                <p>The study was designed by the sponsors in collaboration with an advisory committee. The trial received approval from site independent institutional review boards or ethics committees and was conducted in accordance with the ethics principles of the Declaration of Helsinki and with Good Clinical Practice guidelines defined by the International Council for Harmonization. All patients provided written informed consent. The trial was sponsored by Seagen Inc (Bothell, WA), Astellas Pharma (Northbrook, IL), and Merck Sharp &amp; Dohme LLC (Rahway, NJ). The authors vouch for the accuracy and completeness of the data and for the adherence of the trial to the Protocol.</p>
              </sec>
              <sec>
                <title>End Points</title>
                <p>The primary end point was confirmed objective response rate (cORR; proportion of patients with a complete or partial response) per RECIST version 1.1 by blinded independent central review (BICR). Secondary end points were cORR by investigator, disease control rate (DCR) by BICR and investigator assessment, duration of response (DOR) and progression-free survival (PFS) by BICR and investigator assessment, OS, and safety and tolerability of EV monotherapy and EV + Pembro. Exploratory end points included biomarkers of activity, including baseline PD-L1 status and nectin-4 expression.</p>
              </sec>
              <sec>
                <title>Assessments</title>
                <p>Investigators assessed and confirmed antitumor activity by reviewing computed tomography scans or magnetic resonance imaging with or without intravenous contrast of the chest, abdomen, and pelvis. Patients were evaluated for response assessments using the same imaging method throughout the study. Bone and brain scans were required at screening and repeated if positive at baseline and/or if clinically indicated. Objective responses were confirmed per RECIST version 1.1, with repeat scans 4-5 weeks after a first documented response. Subsequent response assessments were timed from cycle 1 day 1 and were performed every 9 weeks (±7 days) until 1 year after the first dose and then every 12 weeks (±7 days).</p>
                <p>EV adverse events of special interest (AESIs) are medical concepts/composite terms used to characterize identified and potential risks for EV. AESI time-to-onset is calculated as time from the date of the first dose to the start date of the first treatment emergent event that meets the respective AESI search criteria. TRAEs were determined by the investigator and assessed for both arms. Pembro AESIs (AEOSIs), including immune-mediated adverse events (AEs) and infusion reactions, were evaluated using previously described criteria for Pembro monotherapy.<sup><xref rid="b16" ref-type="bibr">16</xref></sup></p>
                <p>Treatment discontinuations were summarized according to the percentage of patients who had TRAEs leading to discontinuation of either agent, including patients who had TRAEs leading to discontinuation of EV only, Pembro only, or both. Of note, discontinuations because of each agent alone, or both, are counted by patient and are not mutually exclusive.</p>
                <p>Nectin-4 and PD-L1 expression were assessed centrally with archival or freshly obtained formalin-fixed, paraffin-embedded tumor tissue using analytically validated immunohistochemistry (IHC) assays. Nectin-4 expression was evaluated at Q2 Solutions as described previously, and stained slides were scored by a pathologist to generate an H-score (range, 0-300).<sup><xref rid="b27" ref-type="bibr">27</xref></sup> PD-L1 expression was assessed using the Agilent PD-L1 IHC 22C3 pharmDx assay, with stained slides scored by a pathologist to generate a PD-L1 combined positive score (CPS; low, &lt;10; high, ≥10).</p>
              </sec>
              <sec>
                <title>Statistical Analysis</title>
                <p>Efficacy and safety end points were assessed for all patients who received EV + Pembro or EV monotherapy. The sample size was based on the precision of the estimate for objective response rate (ORR) as characterized by 95% CIs. The cORR by BICR was summarized with two-sided 95% CI and calculated using the Clopper-Pearson method for each treatment arm. No statistical comparisons were made between treatment arms; EV monotherapy arm was included for isolation of the monotherapy contribution. Secondary end points, cORR by investigator assessment and DCR by BICR and investigator assessment, were summarized with two-sided 95% CIs using the Clopper-Pearson method. DOR and PFS by BICR and by investigator assessment and OS were analyzed using Kaplan-Meier methodology. ORR, DOR, and PFS are presented by BICR in results.</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>RESULTS</title>
              <sec sec-type="subjects">
                <title>Patient Disposition and Baseline Characteristics</title>
                <p>A total of 151 patients were randomly assigned and 149 received EV + Pembro (N = 76) or EV monotherapy (N = 73; Appendix Table A<xref rid="tblA1" ref-type="table">1</xref>, online only). Two patients, one in each arm, were randomly assigned but never received corresponding study treatment (Fig <xref rid="fig1" ref-type="fig">1</xref>). At data cutoff (June 10, 2022), 29 patients in the combination arm had discontinued treatment but remained in the study in long-term follow-up. The median follow-up on study was 14.8 months (95% CI, 12.9 to 17.3) in the combination arm and 15.0 months (95% CI, 12.7 to 17.4) in the monotherapy arm. The median duration of treatment was 9.0 months (range, 0.6-26.1) in the combination arm with patients receiving a median of 11.0 cycles (range, 1-29). The median duration of treatment was 5.5 months (range, 0.5-26.9) in the monotherapy arm with patients receiving a median of 8.0 cycles (range, 1-33).</p>
                <fig position="float" id="fig1" fig-type="figure">
                  <label>FIG 1.</label>
                  <caption>
                    <p>CONSORT diagram. Screening, allocation, follow-up, and analyses. A patient is considered discontinued from the treatment only if both agents are discontinued, including patients who discontinued both agents because of AE(s) or discontinued the latter of the two agents because of an AE (the other agent may be discontinued because of a non-AE at an earlier time). AE, adverse event; EV, enfortumab vedotin; PD, progressive disease; Pembro, pembrolizumab.</p>
                  </caption>
                  <graphic xlink:href="jco-41-4107-g001" position="float"/>
                </fig>
                <p>In the combination arm, patients were predominately male (71.1%) and White (80.3%), with a median age of 71 years (range, 51-91 years). Most patients had an ECOG PS of 0 (43.4%) or 1 (43.4%). The primary disease location was the lower tract (60.5%). Visceral metastases were present in 84.2% of patients, including 17.1% with liver metastases. At baseline, 57.9% of patients had low PD-L1 expression (defined as CPS &lt; 10) (Table <xref rid="tbl1" ref-type="table">1</xref>). The median nectin-4 H-score at baseline was 262.5 (interquartile range [IQR], 200.0-297.0).</p>
                <table-wrap position="float" id="tbl1">
                  <label>TABLE 1.</label>
                  <caption>
                    <p>Patient Demographics and Disease Characteristics at Baseline</p>
                  </caption>
                  <graphic xlink:href="jco-41-4107-g002" position="float"/>
                </table-wrap>
                <p>Baseline characteristics of patients in the monotherapy arm are summarized in Table <xref rid="tbl1" ref-type="table">1</xref>. The median H-score at baseline was 284.0 (IQR, 240.0-298.0).</p>
              </sec>
              <sec>
                <title>Efficacy</title>
                <p>In patients treated with EV + Pembro (N = 76), the cORR by BICR was 64.5% (95% CI, 52.7 to 75.1; 49 of 76 patients). Eight patients (10.5%) had a complete response; 41 patients (53.9%) achieved a partial response; the median time to response was 2.1 months (range, 1.1-6.6; Fig <xref rid="fig2" ref-type="fig">2</xref>). A total of 97.1% of assessable patients had a reduction in their target lesions per BICR (Fig <xref rid="fig2" ref-type="fig">2</xref>). The median DOR per BICR has not yet been reached; 65.4% of responders maintained a response at 12 months (Fig <xref rid="fig3" ref-type="fig">3</xref>). The DCR was 86.8% (95% CI, 77.1 to 93.5; 66 of 76 patients). The PFS rate per BICR at 6 and 12 months was 73.8% and 55.1%, respectively, and the OS rate at 6 and 12 months was 88.2% and 80.7%, respectively (Fig <xref rid="fig4" ref-type="fig">4</xref>). The median OS was 22.3 months (95% CI, 19.09 to not achieved) with 54 (of 76) patients remaining on study for OS follow-up at the time of data cutoff (Appendix Fig A<xref rid="figA1" ref-type="fig">1</xref>, online only).</p>
                <fig position="float" id="fig2" fig-type="figure">
                  <label>FIG 2.</label>
                  <caption>
                    <p>(A) Best overall response by BICR. (B) Antitumor activity of EV + Pembro, waterfall plot of percentage reduction of tumor size from baseline of target lesions by BICR per RECIST v1.1. BICR, blinded independent central review; CPS, combined positive score; CR, complete response; EV, enfortumab vedotin; ORR, objective response rate; PD, progressive disease; Pembro, pembrolizumab; PR, partial response.</p>
                  </caption>
                  <graphic xlink:href="jco-41-4107-g003" position="float"/>
                </fig>
                <fig position="float" id="fig3" fig-type="figure">
                  <label>FIG 3.</label>
                  <caption>
                    <p>(A) Durations of response per BICR by RECIST v1.1. (B) Kaplan-Meier estimate of durations of response per BICR, EV + Pembro treatment arm. (C) Kaplan-Meier estimate of durations of response per BICR, EV monotherapy treatment arm. This study was not designed with statistical comparison between the two treatment arms; direct comparisons should not be made. BICR, blinded independent central review; DOR, duration of response; EV, enfortumab vedotin; mDOR, median duration of response; mono, monotherapy; PD, progressive disease; Pembro, pembrolizumab; v1.1, version 1.1.</p>
                  </caption>
                  <graphic xlink:href="jco-41-4107-g004" position="float"/>
                </fig>
                <fig position="float" id="fig4" fig-type="figure">
                  <label>FIG 4.</label>
                  <caption>
                    <p>EV + Pembro. (A) PFS per BICR, by RECIST v1.1, OS, and median follow-up time. (B) Kaplan-Meier estimate of PFS per BICR by RECIST v1.1. (C) Kaplan-Meier estimate of OS. Preliminary mPFS and mOS are reported here and are expected to evolve over time. At the time of data cutoff, 54 (of 76) patients remain on study for OS follow-up. BICR, blinded independent central review; EV, enfortumab vedotin; mOS, median overall survival; mPFS, median progression-free survival; OS, overall survival; Pembro, pembrolizumab; PFS, progression-free survival; v1.1, version 1.1.</p>
                  </caption>
                  <graphic xlink:href="jco-41-4107-g005" position="float"/>
                </fig>
                <p>The cORR in prespecified subgroups in the combination arm (including PD-L1 expression, liver metastasis, ECOG PS, and primary disease site of origin) was consistent with overall cORR (Appendix Fig A<xref rid="figA2" ref-type="fig">2</xref>, online only).</p>
                <p>Nectin-4 expression was generally high as indicated by median H-score in the combination arm, and the distribution was similar between responders (median, 260.0; IQR, 200.0-297.0) and nonresponders (270.0; 155.0-300.0; Appendix Fig A<xref rid="figA3" ref-type="fig">3</xref>, online only).</p>
                <p>In the monotherapy arm, the cORR per BICR was 45.2% (95% CI, 33.5 to 57.3; 33 of 73 patients; Fig <xref rid="fig2" ref-type="fig">2</xref>). The DOR was 13.2 months (range, 6.14-15.97), and the median time to response was 2.1 months (range, 1.9-15.4). The DCR was 79.5% (95% CI, 68.4 to 88.0; 58 of 73 patients). The 12-month PFS and OS were 35.8% and 70.7%, respectively (Fig <xref rid="fig5" ref-type="fig">5</xref>). The cORR per BICR for prespecified subgroups can be found in Appendix Figure A<xref rid="figA2" ref-type="fig">2</xref>. The nectin-4 H-score median and distribution were similar between responders and nonresponders (Appendix Fig A<xref rid="figA3" ref-type="fig">3</xref>).</p>
                <fig position="float" id="fig5" fig-type="figure">
                  <label>FIG 5.</label>
                  <caption>
                    <p>EV monotherapy. (A) PFS per BICR by RECIST v1.1, OS, and median follow-up time. (B) Kaplan-Meier estimates of PFS per BICR by RECIST v1.1. (C) Kaplan-Meier estimates of OS. Preliminary mPFS and mOS are reported here and are expected to evolve over time. At the time of data cutoff, 46 (of 73) patients remain on study for OS follow-up. BICR, blinded independent central review; EV, enfortumab vedotin; mOS, median overall survival; mPFS, median progression-free survival; OS, overall survival; PFS, progression-free survival; v1.1, version 1.1.</p>
                  </caption>
                  <graphic xlink:href="jco-41-4107-g006" position="float"/>
                </fig>
                <p>The concordance rate of best overall response per RECIST between BICR and investigator assessments was 86.7% in the combination arm and 85.5% in the monotherapy arm.</p>
              </sec>
              <sec>
                <title>Safety</title>
                <p>In patients treated with the combination, the most common TRAEs were fatigue, peripheral sensory neuropathy, alopecia, and maculopapular rash; the most common grade 3 or higher event was maculopapular rash (Table <xref rid="tbl2" ref-type="table">2</xref>). Eighteen (23.7%) patients experienced a serious TRAE, and three (3.9%) patients died due to a TRAE (respiratory failure, pneumonitis, and sepsis). TRAEs leading to dose interruptions of either EV or Pembro occurred in 68.4% of patients. TRAEs leading to discontinuation of EV and/or Pembro are listed in Table <xref rid="tbl2" ref-type="table">2</xref>. The most frequently occurring TRAEs leading to discontinuation of either agent was peripheral neuropathy (nine of 76 patients, 11.8%) and of EV only was peripheral neuropathy (nine of 76 patients, 11.8%) and Pembro only was pneumonitis (three of 76 patients, 3.9%). TRAEs leading to discontinuation of both agents were peripheral motor neuropathy, myasthenia gravis, pneumonitis, and sepsis (one patient [1.3%] each).</p>
                <table-wrap position="float" id="tbl2">
                  <label>TABLE 2.</label>
                  <caption>
                    <p>TRAEs</p>
                  </caption>
                  <graphic xlink:href="jco-41-4107-g007" position="float"/>
                </table-wrap>
                <p>Treatment-related EV AESIs in the combination arm were peripheral neuropathy (46 of 76 patients, 60.5%), skin reactions (51 of 76 patients, 67.1%), hyperglycemia (11 of 76 patients, 14.5%), ocular events (20 of 76 patients, 26.3%), and infusion-related reactions (three of 76 patients, 3.9%; Appendix Table A<xref rid="tblA2" ref-type="table">2</xref>, online only). Grade 3 or higher skin reactions, peripheral neuropathy, and hyperglycemia in the combination arm occurred in 16 of 76 (21.1%), two of 76 (2.6%), and five of 76 (6.6%) patients, respectively. No serious skin reactions occurred, including no severe cutaneous adverse reaction events. One patient experienced serious peripheral neuropathy (1.3%).</p>
                <p>The most frequent Pembro treatment-emergent AEOSIs in the combination arm were severe skin reactions (21 of 76 patients, 27.6%) and hypothyroidism (10 of 76 patients, 13.2%); the most common grade 3 or higher AEOSIs were severe skin reactions (15 of 76 patients, 19.7%) and pneumonitis (four of 76 patients, 5.3%; Appendix Table A<xref rid="tblA3" ref-type="table">3</xref>, online only). Pembro AEOSIs associated with the use of systemic steroids are reported in the Protocol.</p>
                <p>TRAEs and deaths in patients treated with monotherapy are summarized in Table <xref rid="tbl2" ref-type="table">2</xref>. The most frequent treatment-related EV AESIs reported in patients in the monotherapy arm were peripheral neuropathy and skin reactions (Appendix Table A<xref rid="tblA2" ref-type="table">2</xref>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>DISCUSSION</title>
              <p>Approximately half of all patients with la/mUC are unfit for 1L cisplatin-based chemotherapy, and limited 1L therapeutic options exist for these patients.<sup><xref rid="b20" ref-type="bibr">20</xref>,<xref rid="b28" ref-type="bibr">28</xref></sup> Carboplatin plus gemcitabine is currently a standard option for cisplatin-ineligible patients but is associated with low response rate (approximately 36%-42%), short DOR (6.3-7.1 months), and relatively poor tolerability.<sup><xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b29" ref-type="bibr">29</xref>,<xref rid="b30" ref-type="bibr">30</xref></sup> In this study of cisplatin-ineligible patients with la/mUC, EV in combination with Pembro showed a 64.5% overall response rate, with responses lasting beyond 1 year for 65.4% of responders, trending similarly with previously disclosed data from EV-103 Dose Escalation/Cohort A.<sup><xref rid="b26" ref-type="bibr">26</xref></sup> Additionally, the median DOR has not yet been reached for the combination arm. These results stand out from historical data for gemcitabine and carboplatin chemotherapy and confirm the findings of EV-103 Dose Escalation/Cohort A. These data suggest that the EV plus Pembro combination represents a potential new therapeutic option as a 1L regimen for cisplatin-ineligible patients with la/mUC.</p>
              <p>Pembro is an US Food and Drug Administration–approved option that has shown durable responses as monotherapy but is currently restricted in the 1L setting to platinum-ineligible patients.<sup><xref rid="b16" ref-type="bibr">16</xref>,<xref rid="b19" ref-type="bibr">19</xref>,<xref rid="b31" ref-type="bibr">31</xref></sup> Avelumab maintenance therapy has shown a survival benefit compared with observation after platinum-based chemotherapy, but it is only an option for patients who remain free from disease progression after four to six cycles of 1L platinum-based therapy. In fact, modeling data suggest that approximately half of patients with la/mUC may not be eligible for maintenance therapy.<sup><xref rid="b14" ref-type="bibr">14</xref></sup> Despite the availability of these therapies, approximately 60% of cisplatin-ineligible patients with la/mUC who receive 1L treatment never receive 2L treatment, likely because of early progression, tolerability, or short DORs.<sup><xref rid="b20" ref-type="bibr">20</xref></sup> At the time of the primary analysis, the minority of patients in this study had data captured on subsequent therapies; thus this study required additional follow-up to determine whether there is any potential effect from subsequent treatments on patient outcomes.</p>
              <p>A high unmet need remains for a highly efficacious 1L treatment option with rapid and durable responses and a manageable safety profile so that a larger proportion of the cisplatin-ineligible population with la/mUC receives more durable therapeutic benefit. In this study, the overall response rates reported for patients in Cohort K (from either arm) numerically exceeded those reported in trials for the current standard for cisplatin-ineligible patients, gemcitabine plus carboplatin, or for PD-1/PD-L1 CPIs as monotherapies.<sup><xref rid="b16" ref-type="bibr">16</xref>,<xref rid="b17" ref-type="bibr">17</xref>,<xref rid="b19" ref-type="bibr">19</xref>,<xref rid="b32" ref-type="bibr">32</xref>,<xref rid="b33" ref-type="bibr">33</xref></sup></p>
              <p>Although the primary objective was to evaluate the efficacy and safety of the combination, the monotherapy arm was studied to characterize the activity of EV alone in this patient population. The overall response rate of patients treated with EV in the monotherapy arm was 45.2%. The monotherapy arm demonstrated a manageable safety profile, consistent with previous EV monotherapy studies.<sup><xref rid="b22" ref-type="bibr">22</xref>,<xref rid="b26" ref-type="bibr">26</xref>,<xref rid="b34" ref-type="bibr">34</xref></sup></p>
              <p>The ORRs observed in this study were consistent across a range of prespecified subgroups, including patients with liver metastases, and antitumor activity was seen regardless of PD-L1 status. High nectin-4 expression was observed, and the median and distribution was similar between responders and nonresponders. The preliminary PFS and OS results reported here are promising, and data will evolve with additional follow-up, which are trending similarly to median OS found in previously disclosed Dose Escalation/Cohort A data. The safety profile of the combination was manageable and consistent with results from Cohort A of EV-103, with no new safety concerns emerging.<sup><xref rid="b26" ref-type="bibr">26</xref>,<xref rid="b35" ref-type="bibr">35</xref></sup></p>
              <p>Most skin reactions and peripheral neuropathy events were grade ≤ 2 in severity, consistent with observations in the previously reported results for EV-103 Dose Escalation/Cohort A. Skin reactions (including the Pembro AEOSI category of severe skin reactions) and pneumonitis are an identified part of the safety profile for both EV and Pembro monotherapy and were more frequently observed in the combination arm. Higher rates of skin reactions were managed with EV treatment interruption, dose reduction, treatment discontinuation (EV and/or Pembro), and/or corticosteroids, as previously described.<sup><xref rid="b36" ref-type="bibr">36</xref>,<xref rid="b37" ref-type="bibr">37</xref></sup> The safety results highlight the importance of educating both health care practitioners and patients; early intervention for AEs are key components of successfully treating patients with the combination.</p>
              <p>It is important to note that this study was not designed to make statistical comparisons between arms. Similarly, although the cORR found in the EV + Pembro cohort is numerically higher than contemporary studies, including even cisplatin-based chemotherapy arms, the study was not designed as a direct comparison with current standard-of-care regimens. This study builds on the promising results from Dose Escalation/Cohort A and further justifies the ongoing investigation of EV with Pembro in a randomized, phase III study compared with cisplatin or carboplatin plus gemcitabine in biomarker-unselected 1L patients (EV-302/KN-A39, ClinicalTrials.gov identifier: <ext-link xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04223856" ext-link-type="uri">NCT04223856</ext-link>). EV + Pembro are also being evaluated in muscle invasive bladder cancer in randomized phase III trials (EV-303/KN-905, ClinicalTrials.gov identifier: <ext-link xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT03924895" ext-link-type="uri">NCT03924895</ext-link> and EV-304/KNK-B15, ClinicalTrials.gov identifier: <ext-link xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04700124" ext-link-type="uri">NCT04700124</ext-link>).</p>
              <p>In conclusion, in the 1L cisplatin-ineligible la/mUC patient population with high unmet need, EV + Pembro had a manageable safety profile and resulted in a high ORR with durable responses and encouraging PFS and OS results, which will evolve with follow-up. These results from Cohort K add to the previously reported results from Dose Escalation/Cohort A of this study and indicate that this combination may represent a new 1L treatment option for a patient population with high unmet need.</p>
            </sec>
          </body>
          <back>
            <ack>
              <title>ACKNOWLEDGMENT</title>
              <p>We thank the patients who participated in this study, their families, the investigators, and staff at EV-103 clinical study sites, and the members of the safety monitoring committee. We acknowledge the medical monitoring of the study, the entire EV-103 study team, Ray Liao (Seagen Inc, Safety) and Leah Hogdal (Seagen Inc, Biomarkers). Hanna Thomsen, PhD, of Seagen Inc (Bothell, WA) provided medical writing and editorial support, in accordance with Good Publication Practice guidelines.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p>See accompanying Editorial, p. <related-article related-article-type="companion" ext-link-type="doi" id="ra1" xlink:href="10.1200/JCO.23.00987">4084</related-article></p>
              </fn>
            </fn-group>
            <fn-group content-type="presented-at">
              <title>PRIOR PRESENTATION</title>
              <fn specific-use="presented-at" fn-type="presented-at">
                <p>Presented at the 2022 European Society for Medical Oncology Congress, Paris, France, September 12, 2022.</p>
              </fn>
            </fn-group>
            <fn-group content-type="supported-by">
              <title>SUPPORT</title>
              <fn specific-use="supported-by" fn-type="supported-by">
                <p>Supported by Astellas Pharma US; Merck Sharp &amp; Dohme Corp, a subsidiary of Merck &amp; Co Inc, Kenilworth, NJ; and Seagen Inc, EV-103/KN-869. Supported by the National Cancer Institute of the National Institutes of Health under Award No. K12CA076917 (C.J.H.). Supported in part by National Cancer Institute Cancer Center Support Grant No. P30 CA008748.</p>
              </fn>
            </fn-group>
            <sec sec-type="trial">
              <title>CLINICAL TRIAL INFORAMATION</title>
              <p>
                <ext-link xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT03288545" ext-link-type="uri">NCT03288545</ext-link>
              </p>
            </sec>
            <sec sec-type="data-availability">
              <title>DATA SHARING STATEMENT</title>
              <p>Deidentified patient-level trial data that underlie the results reported in this publication will be made available on a case-by-case basis to researchers who provide a methodologically sound proposal. Additional documentation may also be made available. Data availability will begin after approval of the qualified request and end 30 days after receipt of data sets. All requests can be submitted to <email>CTDR@seagen.com</email> and will be reviewed by an internal review committee. Please note that the data sharing policy of this clinical study's sponsor, Seagen Inc, requires all requests for clinical trial data be reviewed to determine the qualification of the specific request. This policy is available at <ext-link xlink:href="https://www.seagen.com/healthcare-professionals/clinical-data-requests" ext-link-type="uri">https://www.seagen.com/healthcare-professionals/clinical-data-requests</ext-link> and is aligned with BIO's Principles on Clinical Trial Data Sharing (available at <ext-link xlink:href="https://www.bio.org/blogs/principles-clinical-trial-data-sharing-reaffirm-commitment" ext-link-type="uri">https://www.bio.org/blogs/principles-clinical-trial-data-sharing-reaffirm-commitment</ext-link>).</p>
            </sec>
            <sec sec-type="contributed">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Conception and design:</bold> Daniel P. Petrylak, Christopher J. Hoimes, Terence W. Friedlander, Saby George, Anne-Sophie Carret, Yao Yu, Blanca Homet Moreno, Jonathan E. Rosenberg</p>
              <p><bold>Provision of study materials or patients:</bold> Peter H. O'Donnell, Matthew I. Milowsky, Thomas W. Flaig, Sandy Srinivas, Saby George, Sergio Bracarda, Jose Pablo Maroto Rey, Jonathan E. Rosenberg</p>
              <p><bold>Collection and assembly of data:</bold> Peter H. O'Donnell, Christopher J. Hoimes, Thomas W. Flaig, Nataliya Mar, Helen H. Moon, Terence W. Friedlander, Rana R. McKay, Sandy Srinivas, Chethan Ramamurthy, Saby George, Sergio Bracarda, Delphine Borchiellini, Jose Pablo Maroto Rey, Christiano Ferrario, Anne-Sophie Carret, Yao Yu, Maria Guseva, Jonathan E. Rosenberg</p>
              <p><bold>Data analysis and interpretation:</bold> Peter H. O'Donnell, Matthew I. Milowsky, Daniel P. Petrylak, Christopher J. Hoimes, Thomas W. Flaig, Nataliya Mar, Terence W. Friedlander, Rana R. McKay, Mehmet A. Bilen, Sandy Srinivas, Earle F. Burgess, Chethan Ramamurthy, Saby George, Daniel M. Geynisman, Sergio Bracarda, Lionnel Geoffrois, Christiano Ferrario, Anne-Sophie Carret, Yao Yu, Maria Guseva, Blanca Homet Moreno, Jonathan E. Rosenberg</p>
              <p><bold>Manuscript writing:</bold> All authors</p>
              <p><bold>Final approval of manuscript:</bold> All authors</p>
              <p><bold>Accountable for all aspects of the work:</bold> All authors</p>
            </sec>
            <sec sec-type="COI-statement">
              <title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title>
              <sec>
                <title>Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer</title>
                <p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link xlink:href="http://www.asco.org/rwc" ext-link-type="uri">www.asco.org/rwc</ext-link> or <ext-link xlink:href="https://ascopubs.org/jco/authors/author-center" ext-link-type="uri">ascopubs.org/jco/authors/author-center</ext-link>.</p>
                <p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link xlink:href="https://openpaymentsdata.cms.gov/" ext-link-type="uri">Open Payments</ext-link>).</p>
                <fn-group content-type="COI-statement">
                  <fn id="con1" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Peter H. O'Donnell</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Merck, Astellas Pharma, Pfizer, CLD Inc, Axiom Healthcare Strategies, EMD Serono, IntrinsiQ, ISMIE, NAMCP, Seagen, Curio Science, FirstWord, MedLearning Group, Research to Practice, Great Debates and Updates, MJH Life Sciences, Peerview, Vaniam Group, Institute for Enquiring Minds</p>
                    <p><bold>Research Funding:</bold> Boehringer Ingelheim (Inst), Merck (Inst), Genentech/Roche (Inst), AstraZeneca/MedImmune (Inst), Acerta Pharma (Inst), Janssen (Inst), Seagen (Inst), Bristol Myers Squibb (Inst), Astellas Pharma (Inst)</p>
                    <p><bold>Expert Testimony:</bold> Oregon Health &amp; Science University (OHSU)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Curio Science</p>
                    <p><bold>Other Relationship:</bold> Janssen, Nektar, NIH, Dragonfly Therapeutics, G1 Therapeutics</p>
                  </fn>
                  <fn id="con2" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Matthew I. Milowsky</bold>
                    </p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Pfizer, Merck, Gilead Sciences</p>
                    <p><bold>Consulting or Advisory Role:</bold> Loxo/Lilly</p>
                    <p><bold>Research Funding:</bold> Merck (Inst), Roche/Genentech (Inst), Bristol Myers Squibb (Inst), Mirati Therapeutics (Inst), Incyte (Inst), Seagen (Inst), G1 Therapeutics (Inst), Alliance Foundation Trials (Inst), Alliance for Clinical Trials in Oncology (Inst), Clovis Oncology (Inst), Arvinas (Inst), ALX Oncology (Inst), Loxo (Inst), Hoosier Cancer Research Network (Inst)</p>
                    <p><bold>Other Relationship:</bold> Elsevier, Medscape</p>
                  </fn>
                  <fn id="con3" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Daniel P. Petrylak</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Bayer, Exelixis, Pfizer, Roche, Astellas Pharma, AstraZeneca, Lilly, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Incyte, Janssen, Pharmacyclics, Seagen, Urogen Pharma, Advanced Accelerator Applications, Ipsen, Bicycle Therapeutics, Mirati Therapeutics, Monopteros Therapeutics, Regeneron, Gilead Sciences</p>
                    <p><bold>Research Funding:</bold> Progenics (Inst), Sanofi (Inst), Endocyte (Inst), Genentech (Inst), Merck (Inst), Astellas Medivation (Inst), Novartis (Inst), AstraZeneca (Inst), Bayer (Inst), Lilly (Inst), Innocrin Pharma (Inst), MedImmune (Inst), Pfizer (Inst), Roche (Inst), Seagen (Inst), Clovis Oncology (Inst), Bristol Myers Squibb (Inst), Advanced Accelerator Applications (Inst), Agensys (Inst), BioXCel Therapeutics (Inst), Eisai (Inst), Mirati Therapeutics (Inst), Replimune (Inst), Medivation (Inst), Gilead Sciences (Inst)</p>
                    <p><bold>Expert Testimony:</bold> Celgene, Sanofi</p>
                  </fn>
                  <fn id="con4" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Christopher J. Hoimes</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Seagen</p>
                    <p><bold>Consulting or Advisory Role:</bold> Bristol Myers Squibb, Eisai, Prometheus, Seagen, Genentech/Roche, Merck Sharp &amp; Dohme, 2bPrecise</p>
                    <p><bold>Speakers' Bureau:</bold> Bristol Myers Squibb, Genentech/Roche, Astellas Pharma, Seagen, Eisai</p>
                    <p><bold>Research Funding:</bold> Merck Sharp &amp; Dohme (Inst), Janssen Oncology (Inst), Novartis (Inst), Alkermes (Inst), Dynavax Technologies (Inst), Nektar (Inst), NanoCarrier (Inst), Seagen (Inst), Astellas Pharma (Inst), Bristol Myers Squibb Foundation (Inst), BioNTech SE (Inst), Crispr Therapeutics (Inst), NeoImmuneTech (Inst), Mirati Therapeutics (Inst)</p>
                    <p><bold>Uncompensated Relationships:</bold> 2bPrecise (Inst)</p>
                  </fn>
                  <fn id="con5" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Thomas W. Flaig</bold>
                    </p>
                    <p><bold>Leadership:</bold> Aurora Oncology, University of Colorado/UC Health</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Aurora Oncology</p>
                    <p><bold>Consulting or Advisory Role:</bold> Seagen, Janssen Oncology</p>
                    <p><bold>Research Funding:</bold> Novartis, Bavarian Nordic, Dendreon, GTx, Janssen Oncology, Medivation, Sanofi, Pfizer, Bristol Myers Squibb, Roche/Genentech, Exelixis, Aragon Pharmaceuticals, Sotio, Tokai Pharmaceuticals, Astrazeneca/MedImmune, Lilly, Astellas Pharma, Agensys, Seagen, La Roche-Posay, Merck, Seagen, Myovant Sciences, Criterium</p>
                    <p><bold>Patents, Royalties, Other Intellectual Property:</bold> The University of Colorado has filed 2 patents in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or in active clinical development right now (eg, neither are in clinical trials)</p>
                  </fn>
                  <fn id="con6" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Nataliya Mar</bold>
                    </p>
                    <p><bold>Speakers' Bureau:</bold> Seagen, Astellas Pharma, Aveo, Eisai, Tempus</p>
                  </fn>
                  <fn id="con7" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Helen H. Moon</bold>
                    </p>
                    <p><bold>Honoraria:</bold> EMD Serono, Pfizer/EMD Serono</p>
                    <p><bold>Research Funding:</bold> Bristol Myers Squibb (Inst), Amgen (Inst), Prometheus (Inst), Genentech (Inst), Seagen (Inst), Arcus Biosciences (Inst), Apollomics (Inst), Nektar (Inst), Revimmune (Inst), HUYA Bioscience International (Inst), Aveo (Inst), Xenocor (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Aveo, Seagen</p>
                  </fn>
                  <fn id="con8" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Terence W. Friedlander</bold>
                    </p>
                    <p><bold>Leadership:</bold> Med BioGene</p>
                    <p><bold>Honoraria:</bold> EMD Serono, AstraZeneca/MedImmune, Astellas Scientific and Medical Affairs Inc, Astellas Pharma</p>
                    <p><bold>Consulting or Advisory Role:</bold> Dava Oncology, EMD Serono, Merck, Astellas Pharma, Foundation Medicine, Basilea, Taiho Oncology, Seagen, AADi</p>
                    <p><bold>Research Funding:</bold> Seagen (Inst), Bristol Myers Squibb (Inst), Neon Therapeutics (Inst), Roche/Genentech (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> AstraZeneca/MedImmune, Genentech/Roche, Jounce Therapeutics, Astellas Pharma</p>
                  </fn>
                  <fn id="con9" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Rana R. McKay</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Janssen, Novartis, Tempus, Exelixis, Pfizer, Bristol Myers Squibb, Astellas Medivation, Astellas Medivation, Bayer, Sanofi, Merck, Vividion Therapeutics, Calithera Biosciences, AstraZeneca, Myovant Sciences, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seagen, Telix Pharmaceuticals, Lilly</p>
                    <p><bold>Research Funding:</bold> Pfizer (Inst), Bayer (Inst), Tempus (Inst)</p>
                  </fn>
                  <fn id="con10" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Mehmet A. Bilen</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Exelixis, Sanofi, Nektar, EMD Serono, Eisai, Janssen, Genomic Health, Pfizer, Bristol Myers Squibb, Bayer, Calithera Biosciences, AstraZeneca, Seagen</p>
                    <p><bold>Research Funding:</bold> Bayer (Inst), Bristol Myers Squibb (Inst), Genentech/Roche (Inst), Incyte (Inst), Nektar (Inst), AstraZeneca (Inst), Tricon Pharmaceuticals (Inst), Pfizer (Inst), Seagen (Inst), Xencor (Inst), Exelixis (Inst), Advanced Accelerator Applications (Inst), Genome &amp; Company (Inst), Peloton Therapeutics (Inst), Merck (Inst), NiKang Therapeutics (Inst)</p>
                  </fn>
                  <fn id="con11" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Sandy Srinivas</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Eisai, Bayer, Bristol Myers Squibb, Merck, AstraZeneca, Seagen, Janssen Oncology, Novartis</p>
                    <p><bold>Research Funding:</bold> Bristol Myers Squibb (Inst), Genentech (Inst), Merck (Inst), Exelixis (Inst), Eisai (Inst), Bayer (Inst), AstraZeneca (Inst), Seattle Genetics/Astellas (Inst)</p>
                    <p><bold>Other Relationship:</bold> Pfizer</p>
                  </fn>
                  <fn id="con12" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Earle F. Burgess</bold>
                    </p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Exelixis, Becton Dickinson, Calithera Biosciences, Gilead Sciences, Medtronic, Macrogenics, Arvinas</p>
                    <p><bold>Honoraria:</bold> Exelixis, Janssen Oncology, Novartis, Pfizer, Merck</p>
                    <p><bold>Consulting or Advisory Role:</bold> Johnson &amp; Johnson</p>
                    <p><bold>Speakers' Bureau:</bold> AstraZeneca, Exelixis</p>
                    <p><bold>Research Funding:</bold> Pfizer, Astellas Pharma</p>
                  </fn>
                  <fn id="con13" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Chethan Ramamurthy</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Gilead Sciences</p>
                    <p><bold>Consulting or Advisory Role:</bold> Seagen, Exelixis</p>
                    <p><bold>Research Funding:</bold> Dispersol (Inst), Novartis (Inst), Seagen (Inst), Gilead Sciences (Inst), Mirati Therapeutics (Inst), Nuvation Bio (Inst)</p>
                  </fn>
                  <fn id="con14" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Saby George</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Bristol Myers Squibb, Bayer, Pfizer, Exelixis, Corvus Pharmaceuticals, Sanofi, EMD Serono, Seattle Genetics/Astellas, Eisai, Merck, Aveo, QED Therapeutics</p>
                    <p><bold>Research Funding:</bold> Pfizer (Inst), Merck (Inst), Agensys (Inst), Novartis (Inst), Bristol Myers Squibb (Inst), Bayer (Inst), Eisai (Inst), Seattle Genetics/Astellas (Inst), Surface Oncology (Inst), Exelixis (Inst), Aravive (Inst), Aveo (Inst), Gilead Sciences (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Bristol-Myers Squibb/Medarex, Sanofi</p>
                  </fn>
                  <fn id="con15" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Daniel M. Geynisman</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Pfizer, Exelixis, AstraZeneca, Seattle Genetics/Astellas, Merck, Myovant Sciences, Bristol Myers Squibb</p>
                    <p><bold>Research Funding:</bold> Genentech (Inst), Merck (Inst), Calithera Biosciences (Inst), Astellas Pharma (Inst), Harpoon Therapeutics (Inst)</p>
                  </fn>
                  <fn id="con16" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Sergio Bracarda</bold>
                    </p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> MSD Oncology, Pfizer</p>
                  </fn>
                  <fn id="con17" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Delphine Borchiellini</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Merck, Bayer, AAA/Endocyte/Novartis</p>
                    <p><bold>Research Funding:</bold> Astellas Pharma (Inst), AstraZeneca (Inst), Bristol Myers Squibb (Inst), Exelixis (Inst), Infinity Pharmaceuticals (Inst), Janssen (Inst), MSD (Inst), Roche (Inst), Bayer (Inst), Taiho Oncology (Inst), AVEO (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Bristol Myers Squibb, Janssen, Pfizer, Ipsen, MSD Oncology, Bayer,</p>
                  </fn>
                  <fn id="con18" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Lionnel Geoffrois</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Ipsen, Merck Serono, BMS, Pfizer, MSD, Ipsen, Merck Serono</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Ipsen, Janssen Oncology, MSD Oncology, Merck KGaA, Merck Serono</p>
                  </fn>
                  <fn id="con19" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Jose Pablo Maroto Rey</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Astellas Pharma, Ipsen, BMS, Merck/Pfizer, Bayer, Janssen</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Merck/Pfizer, Bayer</p>
                  </fn>
                  <fn id="con20" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Christiano Ferrario</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Pfizer, Bayer, Novartis, AstraZeneca, Merck, Astellas Pharma, Roche Canada, Knight Pharmaceuticals</p>
                    <p><bold>Consulting or Advisory Role:</bold> Merck, AstraZeneca, Novartis, Roche</p>
                    <p><bold>Speakers' Bureau:</bold> Merck, Knight Therapeutics, AstraZeneca, Novartis</p>
                    <p><bold>Research Funding:</bold> Astellas Pharma (Inst), AstraZeneca (Inst), Bayer (Inst), Lilly (Inst), Merck (Inst), Novartis (Inst), Roche/Genentech (Inst), Sanofi (Inst), Pfizer (Inst), Janssen Oncology (Inst), Zymeworks (Inst), Seagen (Inst), Immunomedics (Inst), Bicycle Therapeutics (Inst), Sermonix Pharmaceuticals (Inst)</p>
                    <p><bold>Expert Testimony:</bold> Seattle Genetics/Astellas</p>
                  </fn>
                  <fn id="con21" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Anne-Sophie Carret</bold>
                    </p>
                    <p><bold>Employment:</bold> Seagen</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Seagen</p>
                    <p><bold>Honoraria:</bold> Seagen</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Seagen</p>
                  </fn>
                  <fn id="con22" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Yao Yu</bold>
                    </p>
                    <p><bold>Employment:</bold> Seagen</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Seagen</p>
                  </fn>
                  <fn id="con23" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Maria Guseva</bold>
                    </p>
                    <p><bold>Employment:</bold> Astellas Pharma</p>
                  </fn>
                  <fn id="con24" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Blanca Homet Moreno</bold>
                    </p>
                    <p><bold>Employment:</bold> Merck Sharp &amp; Dohme</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Merck Sharp &amp; Dohme</p>
                  </fn>
                  <fn id="con25" specific-use="COI-statement" fn-type="other">
                    <p>
                      <bold>Jonathan E. Rosenberg</bold>
                    </p>
                    <p><bold>Honoraria:</bold> UpToDate, Medscape, Peerview, Research To Practice, Clinical Care Options, Physicans' Education Resource, MJH Life Sciences, EMD Serono, Pfizer</p>
                    <p><bold>Consulting or Advisory Role:</bold> Lilly, Merck, Roche/Genentech, AstraZeneca/MedImmune, Bristol Myers Squibb, Seagen, Bayer, BioClin Therapeutics, QED Therapeutics, Pharmacyclics, GlaxoSmithKline, Janssen Oncology, Astellas Pharma, Boehringer Ingelheim, Pfizer/EMD Serono, Mirati Therapeutics, Immunomedics, Tyra Biosciences, Infinity Pharmaceuticals, Gilead Sciences, Hengrui Pharmaceutical, Alligator Bioscience, Imvax</p>
                    <p><bold>Research Funding:</bold> Genentech/Roche (Inst), Seagen (Inst), Bayer (Inst), AstraZeneca (Inst), QED Therapeutics (Inst), Astellas Pharma (Inst)</p>
                    <p><bold>Patents, Royalties, Other Intellectual Property:</bold> Predictor of platinum sensitivity (Inst)</p>
                    <p>No other potential conflicts of interest were reported.</p>
                  </fn>
                </fn-group>
              </sec>
            </sec>
            <notes>
              <fn-group content-type="COI-statement">
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Peter H. O'Donnell</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Merck, Astellas Pharma, Pfizer, CLD Inc, Axiom Healthcare Strategies, EMD Serono, IntrinsiQ, ISMIE, NAMCP, Seagen, Curio Science, FirstWord, MedLearning Group, Research to Practice, Great Debates and Updates, MJH Life Sciences, Peerview, Vaniam Group, Institute for Enquiring Minds</p>
                  <p><bold>Research Funding:</bold> Boehringer Ingelheim (Inst), Merck (Inst), Genentech/Roche (Inst), AstraZeneca/MedImmune (Inst), Acerta Pharma (Inst), Janssen (Inst), Seagen (Inst), Bristol Myers Squibb (Inst), Astellas Pharma (Inst)</p>
                  <p><bold>Expert Testimony:</bold> Oregon Health &amp; Science University (OHSU)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Curio Science</p>
                  <p><bold>Other Relationship:</bold> Janssen, Nektar, NIH, Dragonfly Therapeutics, G1 Therapeutics</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Matthew I. Milowsky</bold>
                  </p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Pfizer, Merck, Gilead Sciences</p>
                  <p><bold>Consulting or Advisory Role:</bold> Loxo/Lilly</p>
                  <p><bold>Research Funding:</bold> Merck (Inst), Roche/Genentech (Inst), Bristol Myers Squibb (Inst), Mirati Therapeutics (Inst), Incyte (Inst), Seagen (Inst), G1 Therapeutics (Inst), Alliance Foundation Trials (Inst), Alliance for Clinical Trials in Oncology (Inst), Clovis Oncology (Inst), Arvinas (Inst), ALX Oncology (Inst), Loxo (Inst), Hoosier Cancer Research Network (Inst)</p>
                  <p><bold>Other Relationship:</bold> Elsevier, Medscape</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Daniel P. Petrylak</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Bayer, Exelixis, Pfizer, Roche, Astellas Pharma, AstraZeneca, Lilly, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Incyte, Janssen, Pharmacyclics, Seagen, Urogen Pharma, Advanced Accelerator Applications, Ipsen, Bicycle Therapeutics, Mirati Therapeutics, Monopteros Therapeutics, Regeneron, Gilead Sciences</p>
                  <p><bold>Research Funding:</bold> Progenics (Inst), Sanofi (Inst), Endocyte (Inst), Genentech (Inst), Merck (Inst), Astellas Medivation (Inst), Novartis (Inst), AstraZeneca (Inst), Bayer (Inst), Lilly (Inst), Innocrin Pharma (Inst), MedImmune (Inst), Pfizer (Inst), Roche (Inst), Seagen (Inst), Clovis Oncology (Inst), Bristol Myers Squibb (Inst), Advanced Accelerator Applications (Inst), Agensys (Inst), BioXCel Therapeutics (Inst), Eisai (Inst), Mirati Therapeutics (Inst), Replimune (Inst), Medivation (Inst), Gilead Sciences (Inst)</p>
                  <p><bold>Expert Testimony:</bold> Celgene, Sanofi</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Christopher J. Hoimes</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Seagen</p>
                  <p><bold>Consulting or Advisory Role:</bold> Bristol Myers Squibb, Eisai, Prometheus, Seagen, Genentech/Roche, Merck Sharp &amp; Dohme, 2bPrecise</p>
                  <p><bold>Speakers' Bureau:</bold> Bristol Myers Squibb, Genentech/Roche, Astellas Pharma, Seagen, Eisai</p>
                  <p><bold>Research Funding:</bold> Merck Sharp &amp; Dohme (Inst), Janssen Oncology (Inst), Novartis (Inst), Alkermes (Inst), Dynavax Technologies (Inst), Nektar (Inst), NanoCarrier (Inst), Seagen (Inst), Astellas Pharma (Inst), Bristol Myers Squibb Foundation (Inst), BioNTech SE (Inst), Crispr Therapeutics (Inst), NeoImmuneTech (Inst), Mirati Therapeutics (Inst)</p>
                  <p><bold>Uncompensated Relationships:</bold> 2bPrecise (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Thomas W. Flaig</bold>
                  </p>
                  <p><bold>Leadership:</bold> Aurora Oncology, University of Colorado/UC Health</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Aurora Oncology</p>
                  <p><bold>Consulting or Advisory Role:</bold> Seagen, Janssen Oncology</p>
                  <p><bold>Research Funding:</bold> Novartis, Bavarian Nordic, Dendreon, GTx, Janssen Oncology, Medivation, Sanofi, Pfizer, Bristol Myers Squibb, Roche/Genentech, Exelixis, Aragon Pharmaceuticals, Sotio, Tokai Pharmaceuticals, Astrazeneca/MedImmune, Lilly, Astellas Pharma, Agensys, Seagen, La Roche-Posay, Merck, Seagen, Myovant Sciences, Criterium</p>
                  <p><bold>Patents, Royalties, Other Intellectual Property:</bold> The University of Colorado has filed 2 patents in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or in active clinical development right now (eg, neither are in clinical trials)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Nataliya Mar</bold>
                  </p>
                  <p><bold>Speakers' Bureau:</bold> Seagen, Astellas Pharma, Aveo, Eisai, Tempus</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Helen H. Moon</bold>
                  </p>
                  <p><bold>Honoraria:</bold> EMD Serono, Pfizer/EMD Serono</p>
                  <p><bold>Research Funding:</bold> Bristol Myers Squibb (Inst), Amgen (Inst), Prometheus (Inst), Genentech (Inst), Seagen (Inst), Arcus Biosciences (Inst), Apollomics (Inst), Nektar (Inst), Revimmune (Inst), HUYA Bioscience International (Inst), Aveo (Inst), Xenocor (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Aveo, Seagen</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Terence W. Friedlander</bold>
                  </p>
                  <p><bold>Leadership:</bold> Med BioGene</p>
                  <p><bold>Honoraria:</bold> EMD Serono, AstraZeneca/MedImmune, Astellas Scientific and Medical Affairs Inc, Astellas Pharma</p>
                  <p><bold>Consulting or Advisory Role:</bold> Dava Oncology, EMD Serono, Merck, Astellas Pharma, Foundation Medicine, Basilea, Taiho Oncology, Seagen, AADi</p>
                  <p><bold>Research Funding:</bold> Seagen (Inst), Bristol Myers Squibb (Inst), Neon Therapeutics (Inst), Roche/Genentech (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> AstraZeneca/MedImmune, Genentech/Roche, Jounce Therapeutics, Astellas Pharma</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Rana R. McKay</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Janssen, Novartis, Tempus, Exelixis, Pfizer, Bristol Myers Squibb, Astellas Medivation, Astellas Medivation, Bayer, Sanofi, Merck, Vividion Therapeutics, Calithera Biosciences, AstraZeneca, Myovant Sciences, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seagen, Telix Pharmaceuticals, Lilly</p>
                  <p><bold>Research Funding:</bold> Pfizer (Inst), Bayer (Inst), Tempus (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Mehmet A. Bilen</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Exelixis, Sanofi, Nektar, EMD Serono, Eisai, Janssen, Genomic Health, Pfizer, Bristol Myers Squibb, Bayer, Calithera Biosciences, AstraZeneca, Seagen</p>
                  <p><bold>Research Funding:</bold> Bayer (Inst), Bristol Myers Squibb (Inst), Genentech/Roche (Inst), Incyte (Inst), Nektar (Inst), AstraZeneca (Inst), Tricon Pharmaceuticals (Inst), Pfizer (Inst), Seagen (Inst), Xencor (Inst), Exelixis (Inst), Advanced Accelerator Applications (Inst), Genome &amp; Company (Inst), Peloton Therapeutics (Inst), Merck (Inst), NiKang Therapeutics (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Sandy Srinivas</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Eisai, Bayer, Bristol Myers Squibb, Merck, AstraZeneca, Seagen, Janssen Oncology, Novartis</p>
                  <p><bold>Research Funding:</bold> Bristol Myers Squibb (Inst), Genentech (Inst), Merck (Inst), Exelixis (Inst), Eisai (Inst), Bayer (Inst), AstraZeneca (Inst), Seattle Genetics/Astellas (Inst)</p>
                  <p><bold>Other Relationship:</bold> Pfizer</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Earle F. Burgess</bold>
                  </p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Exelixis, Becton Dickinson, Calithera Biosciences, Gilead Sciences, Medtronic, Macrogenics, Arvinas</p>
                  <p><bold>Honoraria:</bold> Exelixis, Janssen Oncology, Novartis, Pfizer, Merck</p>
                  <p><bold>Consulting or Advisory Role:</bold> Johnson &amp; Johnson</p>
                  <p><bold>Speakers' Bureau:</bold> AstraZeneca, Exelixis</p>
                  <p><bold>Research Funding:</bold> Pfizer, Astellas Pharma</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Chethan Ramamurthy</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Gilead Sciences</p>
                  <p><bold>Consulting or Advisory Role:</bold> Seagen, Exelixis</p>
                  <p><bold>Research Funding:</bold> Dispersol (Inst), Novartis (Inst), Seagen (Inst), Gilead Sciences (Inst), Mirati Therapeutics (Inst), Nuvation Bio (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Saby George</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Bristol Myers Squibb, Bayer, Pfizer, Exelixis, Corvus Pharmaceuticals, Sanofi, EMD Serono, Seattle Genetics/Astellas, Eisai, Merck, Aveo, QED Therapeutics</p>
                  <p><bold>Research Funding:</bold> Pfizer (Inst), Merck (Inst), Agensys (Inst), Novartis (Inst), Bristol Myers Squibb (Inst), Bayer (Inst), Eisai (Inst), Seattle Genetics/Astellas (Inst), Surface Oncology (Inst), Exelixis (Inst), Aravive (Inst), Aveo (Inst), Gilead Sciences (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Bristol-Myers Squibb/Medarex, Sanofi</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Daniel M. Geynisman</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Pfizer, Exelixis, AstraZeneca, Seattle Genetics/Astellas, Merck, Myovant Sciences, Bristol Myers Squibb</p>
                  <p><bold>Research Funding:</bold> Genentech (Inst), Merck (Inst), Calithera Biosciences (Inst), Astellas Pharma (Inst), Harpoon Therapeutics (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Sergio Bracarda</bold>
                  </p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> MSD Oncology, Pfizer</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Delphine Borchiellini</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Merck, Bayer, AAA/Endocyte/Novartis</p>
                  <p><bold>Research Funding:</bold> Astellas Pharma (Inst), AstraZeneca (Inst), Bristol Myers Squibb (Inst), Exelixis (Inst), Infinity Pharmaceuticals (Inst), Janssen (Inst), MSD (Inst), Roche (Inst), Bayer (Inst), Taiho Oncology (Inst), AVEO (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Bristol Myers Squibb, Janssen, Pfizer, Ipsen, MSD Oncology, Bayer,</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Lionnel Geoffrois</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Ipsen, Merck Serono, BMS, Pfizer, MSD, Ipsen, Merck Serono</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Ipsen, Janssen Oncology, MSD Oncology, Merck KGaA, Merck Serono</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Jose Pablo Maroto Rey</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Astellas Pharma, Ipsen, BMS, Merck/Pfizer, Bayer, Janssen</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Merck/Pfizer, Bayer</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Christiano Ferrario</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Pfizer, Bayer, Novartis, AstraZeneca, Merck, Astellas Pharma, Roche Canada, Knight Pharmaceuticals</p>
                  <p><bold>Consulting or Advisory Role:</bold> Merck, AstraZeneca, Novartis, Roche</p>
                  <p><bold>Speakers' Bureau:</bold> Merck, Knight Therapeutics, AstraZeneca, Novartis</p>
                  <p><bold>Research Funding:</bold> Astellas Pharma (Inst), AstraZeneca (Inst), Bayer (Inst), Lilly (Inst), Merck (Inst), Novartis (Inst), Roche/Genentech (Inst), Sanofi (Inst), Pfizer (Inst), Janssen Oncology (Inst), Zymeworks (Inst), Seagen (Inst), Immunomedics (Inst), Bicycle Therapeutics (Inst), Sermonix Pharmaceuticals (Inst)</p>
                  <p><bold>Expert Testimony:</bold> Seattle Genetics/Astellas</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Anne-Sophie Carret</bold>
                  </p>
                  <p><bold>Employment:</bold> Seagen</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Seagen</p>
                  <p><bold>Honoraria:</bold> Seagen</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Seagen</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Yao Yu</bold>
                  </p>
                  <p><bold>Employment:</bold> Seagen</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Seagen</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Maria Guseva</bold>
                  </p>
                  <p><bold>Employment:</bold> Astellas Pharma</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Blanca Homet Moreno</bold>
                  </p>
                  <p><bold>Employment:</bold> Merck Sharp &amp; Dohme</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Merck Sharp &amp; Dohme</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Jonathan E. Rosenberg</bold>
                  </p>
                  <p><bold>Honoraria:</bold> UpToDate, Medscape, Peerview, Research To Practice, Clinical Care Options, Physicans' Education Resource, MJH Life Sciences, EMD Serono, Pfizer</p>
                  <p><bold>Consulting or Advisory Role:</bold> Lilly, Merck, Roche/Genentech, AstraZeneca/MedImmune, Bristol Myers Squibb, Seagen, Bayer, BioClin Therapeutics, QED Therapeutics, Pharmacyclics, GlaxoSmithKline, Janssen Oncology, Astellas Pharma, Boehringer Ingelheim, Pfizer/EMD Serono, Mirati Therapeutics, Immunomedics, Tyra Biosciences, Infinity Pharmaceuticals, Gilead Sciences, Hengrui Pharmaceutical, Alligator Bioscience, Imvax</p>
                  <p><bold>Research Funding:</bold> Genentech/Roche (Inst), Seagen (Inst), Bayer (Inst), AstraZeneca (Inst), QED Therapeutics (Inst), Astellas Pharma (Inst)</p>
                  <p><bold>Patents, Royalties, Other Intellectual Property:</bold> Predictor of platinum sensitivity (Inst)</p>
                  <p>No other potential conflicts of interest were reported.</p>
                </fn>
              </fn-group>
            </notes>
            <app-group>
              <app id="app1">
                <title>APPENDIX</title>
                <table-wrap position="anchor" id="tblA1">
                  <label>TABLE A1.</label>
                  <caption>
                    <p>Cisplatin-Ineligibility Criteria</p>
                  </caption>
                  <graphic xlink:href="jco-41-4107-g008" position="float"/>
                </table-wrap>
                <table-wrap position="anchor" id="tblA2">
                  <label>TABLE A2.</label>
                  <caption>
                    <p>EV Treatment-Related AEs of Special Interest</p>
                  </caption>
                  <graphic xlink:href="jco-41-4107-g009" position="float"/>
                </table-wrap>
                <table-wrap position="anchor" id="tblA3">
                  <label>TABLE A3.</label>
                  <caption>
                    <p>Pembro AEs of Special Interest</p>
                  </caption>
                  <graphic xlink:href="jco-41-4107-g010" position="float"/>
                </table-wrap>
                <fig position="anchor" id="figA1" fig-type="figure">
                  <label>FIG A1.</label>
                  <caption>
                    <p>Antitumor activity of EV monotherapy. Waterfall plot of percentage reduction of tumor size from baseline of target lesions by blinded independent central review per RECIST version 1.1. CR, complete response; EV, enfortumab vedotin; PR, partial response.</p>
                  </caption>
                  <graphic xlink:href="jco-41-4107-g011" position="float"/>
                </fig>
                <fig position="anchor" id="figA2" fig-type="figure">
                  <label>FIG A2.</label>
                  <caption>
                    <p>Subgroup analysis of ORR in patients treated with EV + Pembro and patients treated with EV monotherapy. <sup>a</sup>One patient had primary disease at both bladder and ureter. CPS, combined positive score; ECOG PS, Eastern Cooperative Oncology Group performance status; EV, enfortumab vedotin; ORR, objective response rate; Pembro, pembrolizumab.</p>
                  </caption>
                  <graphic xlink:href="jco-41-4107-g012" position="float"/>
                </fig>
                <fig position="anchor" id="figA3" fig-type="figure">
                  <label>FIG A3.</label>
                  <caption>
                    <p>H-score of nectin-4 expression at baseline by best overall response by blinded independent central review in responders and nonresponders. (A) EV + pembrolizumab. (B) EV monotherapy. EV, enfortumab vedotin; MAX, maximum; MIN, minimum; Q1, 1st quartile; Q3, 3rd quartile; SD, standard deviation.</p>
                  </caption>
                  <graphic xlink:href="jco-41-4107-g013" position="float"/>
                </fig>
              </app>
            </app-group>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="b1">
                <label>1.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wong</surname>
                      <given-names>MCS</given-names>
                    </name>
                    <name>
                      <surname>Fung</surname>
                      <given-names>FDH</given-names>
                    </name>
                    <name>
                      <surname>Leung</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The global epidemiology of bladder cancer: A joinpoint regression analysis of its incidence and mortality trends and projection</article-title>
                  <source>Sci Rep</source>
                  <volume>8</volume>
                  <fpage>1129</fpage>
                  <year>2018</year>
                  <pub-id pub-id-type="pmid">29348548</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b2">
                <label>2.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Richters</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Aben</surname>
                      <given-names>KKH</given-names>
                    </name>
                    <name>
                      <surname>Kiemeney</surname>
                      <given-names>L</given-names>
                    </name>
                  </person-group>
                  <article-title>The global burden of urinary bladder cancer: An update</article-title>
                  <source>World J Urol</source>
                  <volume>38</volume>
                  <fpage>1895</fpage>
                  <lpage>1904</lpage>
                  <year>2020</year>
                  <pub-id pub-id-type="pmid">31676912</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b3">
                <label>3.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ferlay</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Soerjomataram</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Dikshit</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012</article-title>
                  <source>Int J Cancer</source>
                  <volume>136</volume>
                  <fpage>E359</fpage>
                  <lpage>E386</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">25220842</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b4">
                <label>4.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shah</surname>
                      <given-names>MV</given-names>
                    </name>
                    <name>
                      <surname>McGovern</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Hepp</surname>
                      <given-names>Z</given-names>
                    </name>
                  </person-group>
                  <article-title>Targeted literature review of the burden of illness in urothelial carcinoma</article-title>
                  <source>Value Health</source>
                  <volume>21</volume>
                  <fpage>S32</fpage>
                  <lpage>S33</lpage>
                  <year>2018</year>
                </mixed-citation>
              </ref>
              <ref id="b5">
                <label>5.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dash</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Galsky</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Vickers</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder</article-title>
                  <source>Cancer</source>
                  <volume>107</volume>
                  <fpage>506</fpage>
                  <lpage>513</lpage>
                  <year>2006</year>
                  <pub-id pub-id-type="pmid">16773629</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b6">
                <label>6.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Galsky</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Hahn</surname>
                      <given-names>NM</given-names>
                    </name>
                    <name>
                      <surname>Rosenberg</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy</article-title>
                  <source>J Clin Oncol</source>
                  <volume>29</volume>
                  <fpage>2432</fpage>
                  <lpage>2438</lpage>
                  <year>2011</year>
                  <pub-id pub-id-type="pmid">21555688</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b7">
                <label>7.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Galsky</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Pal</surname>
                      <given-names>SK</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>SW</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the United States</article-title>
                  <source>Bladder Cancer</source>
                  <volume>4</volume>
                  <fpage>227</fpage>
                  <lpage>238</lpage>
                  <year>2018</year>
                  <pub-id pub-id-type="pmid">29732393</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b8">
                <label>8.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Grivas</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Plimack</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Balar</surname>
                      <given-names>AV</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status</article-title>
                  <source>Ann Oncol</source>
                  <volume>28</volume>
                  <fpage>v301</fpage>
                  <year>2017</year>
                </mixed-citation>
              </ref>
              <ref id="b9">
                <label>9.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>De Santis</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bellmunt</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Mead</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986</article-title>
                  <source>J Clin Oncol</source>
                  <volume>30</volume>
                  <fpage>191</fpage>
                  <lpage>199</lpage>
                  <year>2012</year>
                  <pub-id pub-id-type="pmid">22162575</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b10">
                <label>10.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>von der Maase</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Sengelov</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Roberts</surname>
                      <given-names>JT</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer</article-title>
                  <source>J Clin Oncol</source>
                  <volume>23</volume>
                  <fpage>4602</fpage>
                  <lpage>4608</lpage>
                  <year>2005</year>
                  <pub-id pub-id-type="pmid">16034041</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b11">
                <label>11.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bukhari</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Al-Shamsi</surname>
                      <given-names>HO</given-names>
                    </name>
                    <name>
                      <surname>Azam</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <article-title>Update on the treatment of metastatic urothelial carcinoma</article-title>
                  <source>Scientific World Journal</source>
                  <volume>2018</volume>
                  <fpage>5682078</fpage>
                  <year>2018</year>
                  <pub-id pub-id-type="pmid">29977169</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b12">
                <label>12.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kim</surname>
                      <given-names>TJ</given-names>
                    </name>
                    <name>
                      <surname>Cho</surname>
                      <given-names>KS</given-names>
                    </name>
                    <name>
                      <surname>Koo</surname>
                      <given-names>KC</given-names>
                    </name>
                  </person-group>
                  <article-title>Current status and future perspectives of immunotherapy for locally advanced or metastatic urothelial carcinoma: A comprehensive review</article-title>
                  <source>Cancers (Basel)</source>
                  <volume>12</volume>
                  <fpage>e192</fpage>
                  <year>2020</year>
                </mixed-citation>
              </ref>
              <ref id="b13">
                <label>13.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Powles</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Park</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Voog</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma</article-title>
                  <source>N Engl J Med</source>
                  <volume>383</volume>
                  <fpage>1218</fpage>
                  <lpage>1230</lpage>
                  <year>2020</year>
                  <pub-id pub-id-type="pmid">32945632</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b14">
                <label>14.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Galsky</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Wirtz</surname>
                      <given-names>HS</given-names>
                    </name>
                    <name>
                      <surname>Bloudek</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Benchmarking maintenance therapy survival in first-line advanced urothelial carcinoma using disease modeling</article-title>
                  <source>J Clin Oncol</source>
                  <volume>40</volume>
                  <year>2022</year>
                  <issue>16 suppl</issue>
                  <comment>abstr 4575</comment>
                </mixed-citation>
              </ref>
              <ref id="b15">
                <label>15.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stenehjem</surname>
                      <given-names>DD</given-names>
                    </name>
                    <name>
                      <surname>Tran</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Nkrumah</surname>
                      <given-names>MA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer</article-title>
                  <source>Onco Targets Ther</source>
                  <volume>11</volume>
                  <fpage>5973</fpage>
                  <lpage>5989</lpage>
                  <year>2018</year>
                  <pub-id pub-id-type="pmid">30275703</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b16">
                <label>16.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Balar</surname>
                      <given-names>AV</given-names>
                    </name>
                    <name>
                      <surname>Castellano</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>O'Donnell</surname>
                      <given-names>PH</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study</article-title>
                  <source>Lancet Oncol</source>
                  <volume>18</volume>
                  <fpage>1483</fpage>
                  <lpage>1492</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28967485</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b17">
                <label>17.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Galsky</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Arija</surname>
                      <given-names>JÁA</given-names>
                    </name>
                    <name>
                      <surname>Bamias</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): A multicentre, randomised, placebo-controlled phase 3 trial</article-title>
                  <source>Lancet</source>
                  <volume>395</volume>
                  <fpage>1547</fpage>
                  <lpage>1557</lpage>
                  <year>2020</year>
                  <pub-id pub-id-type="pmid">32416780</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b18">
                <label>18.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Powles</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>van der Heijden</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Castellano</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): A randomised, open-label, multicentre, phase 3 trial</article-title>
                  <source>Lancet Oncol</source>
                  <volume>21</volume>
                  <fpage>1574</fpage>
                  <lpage>1588</lpage>
                  <year>2020</year>
                  <pub-id pub-id-type="pmid">32971005</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b19">
                <label>19.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Powles</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Csoszi</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Ozguroglu</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): A randomised, open-label, phase 3 trial</article-title>
                  <source>Lancet Oncol</source>
                  <volume>22</volume>
                  <fpage>931</fpage>
                  <lpage>945</lpage>
                  <year>2021</year>
                  <pub-id pub-id-type="pmid">34051178</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b20">
                <label>20.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sonpavde</surname>
                      <given-names>GP</given-names>
                    </name>
                    <name>
                      <surname>Galsky</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Wright</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma</article-title>
                  <source>J Clin Oncol</source>
                  <volume>40</volume>
                  <year>2022</year>
                  <issue>16 suppl</issue>
                  <comment>abstr 4565</comment>
                </mixed-citation>
              </ref>
              <ref id="b21">
                <label>21.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Powles</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Rosenberg</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Sonpavde</surname>
                      <given-names>GP</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Enfortumab vedotin in previously treated advanced urothelial carcinoma</article-title>
                  <source>N Engl J Med</source>
                  <volume>384</volume>
                  <fpage>1125</fpage>
                  <lpage>1135</lpage>
                  <year>2021</year>
                  <pub-id pub-id-type="pmid">33577729</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b22">
                <label>22.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yu</surname>
                      <given-names>EY</given-names>
                    </name>
                    <name>
                      <surname>Petrylak</surname>
                      <given-names>DP</given-names>
                    </name>
                    <name>
                      <surname>O'Donnell</surname>
                      <given-names>PH</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): A multicentre, single-arm, phase 2 trial</article-title>
                  <source>Lancet Oncol</source>
                  <volume>22</volume>
                  <fpage>872</fpage>
                  <lpage>882</lpage>
                  <year>2021</year>
                  <pub-id pub-id-type="pmid">33991512</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b23">
                <label>23.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Krysko</surname>
                      <given-names>DV</given-names>
                    </name>
                    <name>
                      <surname>Garg</surname>
                      <given-names>AD</given-names>
                    </name>
                    <name>
                      <surname>Kaczmarek</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Immunogenic cell death and DAMPs in cancer therapy</article-title>
                  <source>Nat Rev Cancer</source>
                  <volume>12</volume>
                  <fpage>860</fpage>
                  <lpage>875</lpage>
                  <year>2012</year>
                  <pub-id pub-id-type="pmid">23151605</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b24">
                <label>24.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Doronina</surname>
                      <given-names>SO</given-names>
                    </name>
                    <name>
                      <surname>Toki</surname>
                      <given-names>BE</given-names>
                    </name>
                    <name>
                      <surname>Torgov</surname>
                      <given-names>MY</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Development of potent monoclonal antibody auristatin conjugates for cancer therapy</article-title>
                  <source>Nat Biotechnol</source>
                  <volume>21</volume>
                  <fpage>778</fpage>
                  <lpage>784</lpage>
                  <year>2003</year>
                  <pub-id pub-id-type="pmid">12778055</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b25">
                <label>25.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Challita-Eid</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Satpayev</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models</article-title>
                  <source>Cancer Res</source>
                  <volume>76</volume>
                  <fpage>3003</fpage>
                  <lpage>3013</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">27013195</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b26">
                <label>26.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hoimes</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Flaig</surname>
                      <given-names>TW</given-names>
                    </name>
                    <name>
                      <surname>Milowsky</surname>
                      <given-names>MI</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer</article-title>
                  <source>J Clin Oncol</source>
                  <volume>41</volume>
                  <fpage>22</fpage>
                  <lpage>31</lpage>
                  <year>2023</year>
                  <pub-id pub-id-type="pmid">36041086</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b27">
                <label>27.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rosenberg</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Sridhar</surname>
                      <given-names>SS</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>EV-101: a phase I study of single-agent enfortumab vedotin in patients with Nectin-4-positive solid tumors, including metastatic urothelial carcinoma</article-title>
                  <source>J Clin Oncol</source>
                  <volume>38</volume>
                  <fpage>1041</fpage>
                  <lpage>1049</lpage>
                  <year>2020</year>
                  <pub-id pub-id-type="pmid">32031899</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b28">
                <label>28.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Parikh</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Feld</surname>
                      <given-names>EK</given-names>
                    </name>
                    <name>
                      <surname>Galsky</surname>
                      <given-names>MD</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: A secular trend analysis</article-title>
                  <source>Future Oncol</source>
                  <volume>16</volume>
                  <fpage>4341</fpage>
                  <lpage>4345</lpage>
                  <year>2020</year>
                  <pub-id pub-id-type="pmid">31840537</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b29">
                <label>29.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Galsky</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Arranz</surname>
                      <given-names>JÁ</given-names>
                    </name>
                    <name>
                      <surname>Grande</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130</article-title>
                  <source>Cancer Res</source>
                  <volume>81</volume>
                  <year>2021</year>
                  <comment>abstr CT042</comment>
                </mixed-citation>
              </ref>
              <ref id="b30">
                <label>30.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Powles</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Csoszi</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Ozguroglu</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361</article-title>
                  <source>J Clin Oncol</source>
                  <volume>39</volume>
                  <year>2021</year>
                  <issue>6 suppl</issue>
                  <comment>abstr 450</comment>
                </mixed-citation>
              </ref>
              <ref id="b31">
                <label>31.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vuky</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Balar</surname>
                      <given-names>AV</given-names>
                    </name>
                    <name>
                      <surname>Castellano</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer</article-title>
                  <source>J Clin Oncol</source>
                  <volume>38</volume>
                  <fpage>2658</fpage>
                  <lpage>2666</lpage>
                  <year>2020</year>
                  <pub-id pub-id-type="pmid">32552471</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b32">
                <label>32.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Balar</surname>
                      <given-names>AV</given-names>
                    </name>
                    <name>
                      <surname>Galsky</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Rosenberg</surname>
                      <given-names>JE</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial</article-title>
                  <source>Lancet</source>
                  <volume>389</volume>
                  <fpage>67</fpage>
                  <lpage>76</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">27939400</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b33">
                <label>33.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Galsky</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Mortazavi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Milowsky</surname>
                      <given-names>MI</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer</article-title>
                  <source>J Clin Oncol</source>
                  <volume>38</volume>
                  <fpage>1797</fpage>
                  <lpage>1806</lpage>
                  <year>2020</year>
                  <pub-id pub-id-type="pmid">32271672</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b34">
                <label>34.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rosenberg</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>O'Donnell</surname>
                      <given-names>PH</given-names>
                    </name>
                    <name>
                      <surname>Balar</surname>
                      <given-names>AV</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy</article-title>
                  <source>J Clin Oncol</source>
                  <volume>37</volume>
                  <fpage>2592</fpage>
                  <lpage>2600</lpage>
                  <year>2019</year>
                  <pub-id pub-id-type="pmid">31356140</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b35">
                <label>35.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pace</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Brower</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Conway</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Enfortumab vedotin: Nursing perspectives on the management of adverse events in patients with locally advanced or metastatic urothelial carcinoma</article-title>
                  <source>Clin J Oncol Nurs</source>
                  <volume>25</volume>
                  <fpage>E1</fpage>
                  <lpage>E9</lpage>
                  <year>2021</year>
                  <pub-id pub-id-type="pmid">33739346</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b36">
                <label>36.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lacouture</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Patel</surname>
                      <given-names>AB</given-names>
                    </name>
                    <name>
                      <surname>Rosenberg</surname>
                      <given-names>JE</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin</article-title>
                  <source>Oncologist</source>
                  <volume>27</volume>
                  <fpage>e223</fpage>
                  <lpage>e232</lpage>
                  <year>2022</year>
                  <pub-id pub-id-type="pmid">35274723</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b37">
                <label>37.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Belum</surname>
                      <given-names>VR</given-names>
                    </name>
                    <name>
                      <surname>Benhuri</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Postow</surname>
                      <given-names>MA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor</article-title>
                  <source>Eur J Cancer</source>
                  <volume>60</volume>
                  <fpage>12</fpage>
                  <lpage>25</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">27043866</pub-id>
                </mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
